Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer.

Knox SJ, Jayachandran P, Keeling CA, Stevens KJ, Sandhu N, Stamps-DeAnda SL, Savic R, Shura L, Buyyounouski MK, Grimes K.

Transl Oncol. 2019 Aug 24;12(11):1525-1531. doi: 10.1016/j.tranon.2019.08.006. [Epub ahead of print]

2.

High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer.

Morales-Kastresana A, Musich TA, Welsh JA, Telford W, Demberg T, Wood JCS, Bigos M, Ross CD, Kachynski A, Dean A, Felton EJ, Van Dyke J, Tigges J, Toxavidis V, Parks DR, Overton WR, Kesarwala AH, Freeman GJ, Rosner A, Perfetto SP, Pasquet L, Terabe M, McKinnon K, Kapoor V, Trepel JB, Puri A, Kobayashi H, Yung B, Chen X, Guion P, Choyke P, Knox SJ, Ghiran I, Robert-Guroff M, Berzofsky JA, Jones JC.

J Extracell Vesicles. 2019 Jun 19;8(1):1597603. doi: 10.1080/20013078.2019.1597603. eCollection 2019.

3.

Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.

Gutkin PM, Hiniker SM, Swetter SM, Reddy SA, Knox SJ.

Cureus. 2018 Dec 12;10(12):e3723. doi: 10.7759/cureus.3723.

4.

Development of a biodosimeter for radiation triage using novel blood protein biomarker panels in humans and non-human primates.

Balog RP, Bacher R, Chang P, Greenstein M, Jammalamadaka S, Javitz H, Knox SJ, Lee S, Lin H, Shaler T, Shura L, Stein P, Todd K, Cooper DE.

Int J Radiat Biol. 2019 Jan 3:1-13. doi: 10.1080/09553002.2018.1532611. [Epub ahead of print]

PMID:
30605362
5.

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.

Wei L, Xie Q, Hou JL, Jia J, Li W, Xu M, Li J, Wu S, Cheng J, Jiang J, Wang G, Yang Y, Mou Z, Gao ZL, Gong G, Niu JQ, Hu P, Tang H, Lin F, Dou X, Li L, Zhang LL, Nan Y, Massetto B, Yang JC, Knox SJ, Kersey K, German P, Mo H, Jiang D, Brainard DM, Jiang J, Ning Q, Duan Z.

J Gastroenterol Hepatol. 2018 Jun;33(6):1168-1176. doi: 10.1111/jgh.14102. Epub 2018 Mar 25. Erratum in: J Gastroenterol Hepatol. 2018 Aug;33(8):1554.

PMID:
29380415
6.

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.

Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ.

Gastroenterology. 2018 Mar;154(4):989-997. doi: 10.1053/j.gastro.2017.11.011. Epub 2017 Nov 22.

PMID:
29174546
7.

Alteration of Interneuron Immunoreactivity and Autophagic Activity in Rat Hippocampus after Single High-Dose Whole-Brain Irradiation.

Ouyang YB, Ning S, Adler JR, Maciver B, Knox SJ, Giffard R.

Cureus. 2017 Jun 30;9(6):e1414. doi: 10.7759/cureus.1414.

8.

High Dose Gamma Radiation Selectively Reduces GABAA-slow Inhibition.

Dagne BA, Sunay MK, Cayla NS, Ouyang YB, Knox SJ, Giffard RG, Adler JR, Maciver B.

Cureus. 2017 Mar 4;9(3):e1076. doi: 10.7759/cureus.1076.

9.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

10.

Phase I Trial: SABR and Ipilimumab-Letter.

Hiniker SM, Reddy SA, Swetter SM, Knox SJ.

Clin Cancer Res. 2017 Jan 1;23(1):320. doi: 10.1158/1078-0432.CCR-16-2495. No abstract available.

11.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.

Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review. Erratum in: Expert Opin Investig Drugs. 2017 Feb;26(2):261. Carterg, Corey A [corrected to Carter, Corey A].

12.

Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes.

Shah SR, Rao PN, Sarin SK, Chowdhury A, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VG, Rai RR, Saigal S, Singh D, Trehanpati N, Chen S, Gaggar A, Knox SJ, Subramanian GM, Singh SP, Sood A, Varghese J, Venugopal RV.

Indian J Gastroenterol. 2016 Nov;35(6):469-477. Epub 2016 Nov 15.

PMID:
27844277
13.

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.

Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Garrison KL, Gao B, Knox SJ, Pang PS, Kim YJ, Byun KS, Kim YS, Heo J, Han KH.

Hepatol Int. 2016 Nov;10(6):947-955. Epub 2016 May 20.

PMID:
27198664
14.

Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India.

Tamayo A, Shah SR, Bhatia S, Chowdhury A, Rao PN, Dinh P, Knox SJ, Gaggar A, Subramanian GM, Mohan VG, Sood A, Mehta R, Sarin SK.

Hepatol Int. 2016 Nov;10(6):988-995. Epub 2016 May 4.

15.

Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.

Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, Knox SJ, Bakulin I, Chulanov V.

Antivir Ther. 2016;21(8):671-678. doi: 10.3851/IMP3065. Epub 2016 Jul 4.

PMID:
27376706
16.

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L, Knox SJ.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):578-88. doi: 10.1016/j.ijrobp.2016.07.005. Epub 2016 Jul 15.

17.

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.

Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, Svarovskaia E, Knox SJ, Loustaud-Ratti V, Asselah T.

Hepatology. 2016 Oct;64(4):1049-56. doi: 10.1002/hep.28706. Epub 2016 Jul 29.

PMID:
27351341
18.

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.

Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003.

19.

A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.

Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Mathias A, Han L, Knox SJ, Brainard DM, Kim YJ, Byun KS, Kim YS, Heo J, Han KH.

J Viral Hepat. 2016 May;23(5):358-65. doi: 10.1111/jvh.12499. Epub 2016 Feb 10.

PMID:
26864153
20.

Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.

Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, Chen JJ, Yang JC, Knox SJ, Gao B, Garrison KL, Mo H, Pang PS, Hsu YC, Hu TH, Chu CJ, Kao JH.

J Gastroenterol Hepatol. 2016 Jul;31(7):1323-9. doi: 10.1111/jgh.13305.

PMID:
26841930
21.

A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.

Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL.

Liver Int. 2016 Aug;36(8):1101-7. doi: 10.1111/liv.13082. Epub 2016 Mar 23.

22.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Kim MM, Parmar H, Cao Y, Knox SJ, Oronsky B, Scicinski J, Lawrence TS, Lao CD.

Neuro Oncol. 2016 Mar;18(3):455-6. doi: 10.1093/neuonc/nov317. Epub 2016 Jan 13. No abstract available.

23.

Predictors of clinical response to immunotherapy with or without radiotherapy.

Hiniker SM, Maecker HT, Knox SJ.

J Radiat Oncol. 2015;4:339-345. Epub 2015 Sep 19. Review.

24.

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.

Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH.

Hepatology. 2016 Apr;63(4):1112-9. doi: 10.1002/hep.28425. Epub 2016 Feb 22.

PMID:
26704693
25.

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.

26.

Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.

Lai CL, Wong VW, Yuen MF, Yang JC, Knox SJ, Mo H, Han LL, Brainard DM, Chan HL.

Aliment Pharmacol Ther. 2016 Jan;43(1):96-101. doi: 10.1111/apt.13429. Epub 2015 Oct 26.

27.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR.

Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.

PMID:
26296952
28.

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R.

Oncotarget. 2015 Aug 28;6(25):21547-56.

29.

Elevated Intracranial Pressure and Cerebral Edema following Permanent MCA Occlusion in an Ovine Model.

Wells AJ, Vink R, Helps SC, Knox SJ, Blumbergs PC, Turner RJ.

PLoS One. 2015 Jun 29;10(6):e0130512. doi: 10.1371/journal.pone.0130512. eCollection 2015.

30.

Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, McHutchison JG, Esmat G.

J Hepatol. 2015 Sep;63(3):581-5. doi: 10.1016/j.jhep.2015.04.023. Epub 2015 May 1.

PMID:
25937436
31.

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M.

Lancet Infect Dis. 2015 Jun;15(6):645-53. doi: 10.1016/S1473-3099(15)70099-X. Epub 2015 Apr 8.

PMID:
25863559
32.

CCR 20th anniversary commentary: Radioactive Drones for B-cell lymphoma.

Knox SJ, Levy R.

Clin Cancer Res. 2015 Feb 1;21(3):493-4. doi: 10.1158/1078-0432.CCR-14-2547.

33.

Immunotherapy and radiation.

Hiniker SM, Knox SJ.

Semin Oncol. 2014 Dec;41(6):702-13. doi: 10.1053/j.seminoncol.2014.09.019. Epub 2014 Oct 6. Review.

PMID:
25499631
34.

Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.

Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT.

J Hepatol. 2015 May;62(5):1040-6. doi: 10.1016/j.jhep.2014.10.044. Epub 2014 Nov 5.

35.

Novel human radiation exposure biomarker panel applicable for population triage.

Bazan JG, Chang P, Balog R, D'Andrea A, Shaler T, Lin H, Lee S, Harrison T, Shura L, Schoen L, Knox SJ, Cooper DE.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):612-9. doi: 10.1016/j.ijrobp.2014.05.046. Epub 2014 Jul 29.

PMID:
25084613
36.

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.

Ning S, Bednarski M, Oronsky B, Scicinski J, Knox SJ.

Biochem Biophys Res Commun. 2014 May 9;447(3):537-42. doi: 10.1016/j.bbrc.2014.04.032. Epub 2014 Apr 13.

PMID:
24735538
37.

The influence of branch order on optimal leaf vein geometries: Murray's law and area preserving branching.

Price CA, Knox SJ, Brodribb TJ.

PLoS One. 2013 Dec 31;8(12):e85420. doi: 10.1371/journal.pone.0085420. eCollection 2013.

38.

Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice.

Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK.

J Clin Invest. 2013 Dec;123(12):5361-70. doi: 10.1172/JCI70895. Epub 2013 Nov 15.

39.

Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer.

Tian J, Doi H, Saar M, Santos J, Li X, Peehl DM, Knox SJ.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1179-85. doi: 10.1016/j.ijrobp.2013.08.051. Epub 2013 Oct 24.

PMID:
24210080
40.

Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line.

Parker JJ, Jones JC, Strober S, Knox SJ.

Clin Immunol. 2013 Jul;148(1):44-55. doi: 10.1016/j.clim.2013.03.008. Epub 2013 Mar 26.

41.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A.

Cancer Biother Radiopharm. 2013 Jun;28(5):370-9. doi: 10.1089/cbr.2012.1387. Epub 2013 Mar 26.

PMID:
23530878
42.

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ.

Transl Oncol. 2012 Dec;5(6):404-7. Epub 2012 Dec 1.

43.

The scarlet letter of alkylation: a mini review of selective alkylating agents.

Oronsky BT, Reid T, Knox SJ, Scicinski JJ.

Transl Oncol. 2012 Aug;5(4):226-9. Epub 2012 Aug 1.

44.

A surgical model of permanent and transient middle cerebral artery stroke in the sheep.

Wells AJ, Vink R, Blumbergs PC, Brophy BP, Helps SC, Knox SJ, Turner RJ.

PLoS One. 2012;7(7):e42157. doi: 10.1371/journal.pone.0042157. Epub 2012 Jul 27.

45.

Abscopal effect in a patient with melanoma.

Hiniker SM, Chen DS, Knox SJ.

N Engl J Med. 2012 May 24;366(21):2035; author reply 2035-6. doi: 10.1056/NEJMc1203984. No abstract available.

PMID:
22621637
46.

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials.

Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ.

Cancer Res. 2012 May 15;72(10):2600-8. doi: 10.1158/0008-5472.CAN-11-2303.

47.

Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ.

Clin Cancer Res. 2012 Jun 15;18(12):3366-76. doi: 10.1158/1078-0432.CCR-11-3179. Epub 2012 Apr 25.

48.

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

Oronsky BT, Knox SJ, Scicinski JJ.

Transl Oncol. 2012 Apr;5(2):66-71. Epub 2012 Apr 1.

49.

Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice.

Ning S, Budas GR, Churchill EN, Chen CH, Knox SJ, Mochly-Rosen D.

Radiat Res. 2012 Jul;178(1):69-74. Epub 2012 Mar 9.

50.

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Oronsky BT, Knox SJ, Scicinski J.

Transl Oncol. 2011 Aug;4(4):189-98. Epub 2011 Aug 1.

Supplemental Content

Support Center